Phase 1 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have multiple myeloma that has come back or stopped responding to treatment, and who have previously received a certain number of treatment regimens (the exact number required depends on which part of the trial a person is being considered for — confirm with trial site)
- People whose multiple myeloma can be detected and measured using standard international criteria
- People who are fairly active and able to carry out daily activities, rated 0 or 1 on a standard medical fitness scale (meaning generally well or with only mild symptoms)
- People who are willing and able to follow the trial's requirements around using contraception
Who may not be able to join:
- People who have previously been treated with certain specific drugs, including alnuctamab, mezigdomide, iberdomide, or elranatamab, depending on which part of the trial is being considered (confirm with trial site for which restrictions apply to each section)
- People who have previously received treatments that target a protein called BCMA, depending on which part of the trial is being considered (confirm with trial site)
- People who have previously received treatments that target a protein called GPRC5D
- There are additional criteria not listed here that the trial site will assess
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of adverse events (AEs); Incidence of serious adverse events (SAEs); Incidence of adverse events of special interest (AESI); Incidence of AEs leading to discontinuation; Number of Deaths; Establish recommended Phase 2 dose (RP2D)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.